Fluorescent signs for use in medical devices (Q11207): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: EU contribution (P835): 168,359.3396 euro) |
(Changed an Item: Fixing rounding issue) |
||||||||||||||
| Property / EU contribution | |||||||||||||||
168,359.34 Euro
| |||||||||||||||
| Property / EU contribution: 168,359.34 Euro / rank | |||||||||||||||
Preferred rank | |||||||||||||||
| Property / EU contribution: 168,359.34 Euro / qualifier | |||||||||||||||
exchange rate to Euro: 0.04 Euro
| |||||||||||||||
| Property / EU contribution: 168,359.34 Euro / qualifier | |||||||||||||||
point in time: 10 January 2020
| |||||||||||||||
Revision as of 09:27, 22 September 2020
Project in Czech Republic financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Fluorescent signs for use in medical devices |
Project in Czech Republic financed by DG Regio |
Statements
4,208,983.49 Czech koruna
0 references
10,525,090.0 Czech koruna
0 references
39.99 percent
0 references
20 April 2017
0 references
18 April 2020
0 references
EXBIO Praha, a.s.
0 references
49°59'0.49"N, 14°30'9.11"E
0 references
25250
0 references
Projekt je zaměřen na VaV technologie přípravy specifických fluorescenčních značek, tzv. tandemových fluorochromů, která umožní výrobu skupiny produktů - In vitro diagnostických (IVD) zdravotnických prostředků pro identifikaci maligních, reaktivních a normálních krevních buněk v klinických vzorcích pomocí průtokové cytometrie. Splněním požadavků regulace 21 CFR 820 bude zaručena možnost registrace nových produktů pro klinické aplikace na celosvětových trzích, včetně USA. a. (Czech)
0 references
The project is aimed at R & D for the preparation of specific fluorescent marks, so-called tandem fluorochroms, to enable the production of a product group — In vitro diagnostic (IVD) medical devices to identify malignant, reactive and normal blood cells in clinical samples by flow cytometry. Compliance with the requirements of regulation 21 CFR 820 will guarantee the possibility of registering new products for clinical applications in global markets, including USA. a. (English)
0 references
Identifiers
CZ.01.1.02/0.0/0.0/16_083/0010233
0 references